Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Antonio Vitiello and Francesco Ferrara.
Antonio Vitiello
Connection Strength
28.098
Francesco Ferrara
  1. Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update. Cardiovasc Drugs Ther. 2021 Aug 30.
    View in: PubMed
    Score: 0.965
  2. Plausible Positive Effects of Statins in COVID-19 Patient. Cardiovasc Toxicol. 2021 10; 21(10):781-789.
    View in: PubMed
    Score: 0.956
  3. The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections. Naunyn Schmiedebergs Arch Pharmacol. 2021 07; 394(7):1589-1593.
    View in: PubMed
    Score: 0.952
  4. COVID-19 vaccination in pregnancy. Drugs Ther Perspect. 2021; 37(7):313-314.
    View in: PubMed
    Score: 0.944
  5. Brief review of the mRNA vaccines COVID-19. Inflammopharmacology. 2021 Jun; 29(3):645-649.
    View in: PubMed
    Score: 0.943
  6. Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients. Wien Klin Wochenschr. 2021 09; 133(17-18):983-988.
    View in: PubMed
    Score: 0.941
  7. COVID-19 global pandemic: vaccines and new monoclonal antibodies, aspects to be clarified. Immunol Res. 2021 04; 69(2):115-116.
    View in: PubMed
    Score: 0.940
  8. Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance. Cardiovasc Toxicol. 2021 06; 21(6):498-503.
    View in: PubMed
    Score: 0.939
  9. The advantages of drug treatment with statins in patients with SARS-CoV-2 infection. Wien Klin Wochenschr. 2021 Sep; 133(17-18):958-965.
    View in: PubMed
    Score: 0.937
  10. COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci. 2022 Feb; 191(1):487-488.
    View in: PubMed
    Score: 0.934
  11. Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19. Lung India. 2021 Mar; 38(Supplement):S129-S130.
    View in: PubMed
    Score: 0.932
  12. Colchicine and SARS-CoV-2: Management of the hyperinflammatory state. Respir Med. 2021 03; 178:106322.
    View in: PubMed
    Score: 0.927
  13. Drugs acting on the renin-angiotensin system and SARS-CoV-2. Drug Discov Today. 2021 04; 26(4):870-874.
    View in: PubMed
    Score: 0.925
  14. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. 2021 Apr; 82(4):264-269.
    View in: PubMed
    Score: 0.925
  15. Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn Schmiedebergs Arch Pharmacol. 2021 05; 394(5):1003-1007.
    View in: PubMed
    Score: 0.924
  16. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. 2021 Feb; 147:110486.
    View in: PubMed
    Score: 0.923
  17. Correlation between the use of statins and COVID-19: what do we know? BMJ Evid Based Med. 2020 Dec 02.
    View in: PubMed
    Score: 0.916
  18. Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. 2021 08; 190(3):1249-1250.
    View in: PubMed
    Score: 0.914
  19. Scientific and pharmacological rationale for the treatment of cardiac damage caused by COVID-19. Discov Med. 2020 Nov-Dec; 30(161):155-161.
    View in: PubMed
    Score: 0.911
  20. Antidiabetes Agents against Sars-Cov-2 Infection. SN Compr Clin Med. 2020; 2(12):2718-2721.
    View in: PubMed
    Score: 0.910
  21. Remdesivir and COVID-19. Ir J Med Sci. 2021 08; 190(3):1237-1238.
    View in: PubMed
    Score: 0.908
  22. Therapeutic Strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci. 2021 Jan 01; 156:105579.
    View in: PubMed
    Score: 0.906
  23. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci. 2020 Dec 01; 262:118510.
    View in: PubMed
    Score: 0.905
  24. Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times? Indian J Pharmacol. 2020 Sep-Oct; 52(5):441-442.
    View in: PubMed
    Score: 0.901
  25. COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy. SN Compr Clin Med. 2020 Aug 27; 1-4.
    View in: PubMed
    Score: 0.900
  26. Sacubitril, valsartan and SARS-CoV-2. BMJ Evid Based Med. 2020 Jul 27.
    View in: PubMed
    Score: 0.894
  27. Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know? Eur J Pharmacol. 2020 Sep 15; 883:173373.
    View in: PubMed
    Score: 0.892
  28. The Central Role of Clinical Nutrition in COVID-19 Patients During and After Hospitalization in Intensive Care Unit. SN Compr Clin Med. 2020; 2(8):1064-1068.
    View in: PubMed
    Score: 0.892
  29. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol. 2020 Nov; 76(11):1615-1618.
    View in: PubMed
    Score: 0.889
  30. Worldwide Recommendations and Therapies for Multiple Sclerosis: Are They Safe in the COVID-19 Pandemic Period? SN Compr Clin Med. 2020 Jun 26; 1-2.
    View in: PubMed
    Score: 0.889
  31. [The importance of the logistic warehouse in pandemic period: the experience of the USL Umbria 1 (Perugia, Italy) during covid-19.] Recenti Prog Med. 2021 03; 112(3):219-224.
    View in: PubMed
    Score: 0.233
  32. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021 Nov; 190(4):1637-1638.
    View in: PubMed
    Score: 0.231
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.